Teva Pharmaceutical has reported that the FDA has granted tentative approval to its generic version of Abbott Laboratories' Depakote tablets.

The tentative approval covers 125 milligram, 250 milligram and 500 milligram tablets of delayed-release divalproex sodium, the active ingredient in Depakote, for the treatment of migraine headaches, several types of epileptic disorders, and manic episodes associated with bipolar disorder.